MIAMI, FL--(MARKET WIRE)--Jun 29, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) (“DOR” or the “Company”), a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biodefense countermeasures, today announced the appointment of Cyrille F. Buhrman to its board of directors.
